ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2026
The Effect of Capromorelin and Extended-Release Buprenorphine on Body Weight in Guinea Pigs (Cavia porcellus).
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guinea pigs (Cavia porcellus) are widely used in biomedical research and are sensitive to stress-induced anorexia and weight loss. Buprenorphine extended release (XR) is commonly used for analgesia in laboratory animals but has been associated with decreased appetite and weight loss. Capromorelin, a ghrelin receptor agonist, is FDA-approved to stimulate appetite in dogs and cats. However, its utility in mitigating opioid-associated weight loss in guinea pigs has not been evaluated. This study's primary objective was to evaluate the effects of capromorelin on body weight in guinea pigs, both independently and in conjunction with buprenorphine XR administration, and whether oral capromorelin mitigates the weight loss associated with buprenorphine administration. A secondary objective was to evaluate habituation to voluntary consumption of an oral delivery puree and continued consumption of the puree with capromorelin added. Forty-eight female guinea pigs were randomized into 4 groups (n = 12/group) in a 2 × 2 factorial design. Animals were acclimated for 5 days to receive oral treatments, and all received either oral capromorelin (5 mg/kg) or sham treatment daily for 3 days, combined with either a single subcutaneous dose of buprenorphine XR (0.48 mg/kg) or saline. Body weights were recorded days -7 through -3 and days 0 through 5. All animals accepted oral treatments without the need for oral gavage. Guinea pigs receiving buprenorphine XR experienced significant weight loss compared with controls and were significantly less likely to return to baseline weight. Capromorelin treatment did not significantly affect weight change, and no interaction between capromorelin and buprenorphine XR was observed. Therefore, capromorelin at 5 mg/kg once a day for 3 days did not mitigate weight loss associated with buprenorphine XR administration in guinea pigs. These findings emphasize the need for species-specific evaluation of appetite stimulants and support the value of extended monitoring following administration of long-acting analgesics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.